新型特异性靶向前哨淋巴结示踪剂的研究进展

张晶洁; 张万春; 李晓敏; 马乐; 张晶洁; 张万春; 李晓敏; 马乐

doi:10.3760/cma.j.issn.1673-4114.2018.01.013

[1]

Lucci A, Mccall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011[J]. J Clin Oncol, 2007, 25(24):3657-3663.DOI:10.1200/JCO.2006.07.4062.

[2]

Bluemel C, Herrmann K, Giammarile FA, et al. EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma[J]. Eur J Nucl Med Mol Imaging, 2015, 42(11):1750-1766. DOI:10.1007/s00259-015-3135-1.

[3]

Wallace AM, Hoh CK, Vera DR, et al. Lymphoseek:a molecular radiopharmaceutical for sentinel node detection[J]. Ann Surg Oncol, 2003, 10(5):531-538. DOI:10.1245/ASO.2003.07.012.

[4]

Cragg MS, Walshe CA, Ivanov AO, et al.The biology of CD20 and its potential as a target for mAb therapy[J]. Curr Dir Autoimmun, 2005, 8:140-174. DOI:10.1159/000082102.

[5]

王雪鹃, 杨志, 林保和, 等.前哨淋巴结显像剂⁹⁹Tc^m-IT-Rituximab的制备及其定位性能[J].中华核医学与分子影像杂志, 2006, 26(4):226-230. DOI:10.3760/cma.j.issn.2095-2848.2006.04.010.
Wang XJ, Yang Z, Lin BH, et al. The preparation and localization study of a novel sentinel lymphoscintigraphy agent ⁹⁹Tc^m-IT-Rituximab[J]. Chin J Nucl Med Mol Imaging, 2006, 26(4):226-230. DOI:10.3760/cma.j.issn.2095-2848.2006.04.010.

[6]

Stopar TG, Mlinaric-Rascan I, Fettich J, et al. Tc-99m-rituximab radiolabelled by photo-activation:a new non-Hodgkin's lymphoma imaging agent[J]. Eur J Nucl Med Mol Imaging, 2006, 33(1):53-59. DOI:10.1007/s00259-005-1838-4.

[7]

Malviya G, Anzola KL, Podestà E, et al. ^99mTc-labeled rituximab for Imaging B lymphocyte infiltration in inflammatory autoimmune disease patients[J].Mol Imaging Biol, 2012, 14(5):637-646. doi: 10.1007/s11307-011-0527-x

[8]

Pandey U, Kameswaran M, Sarma HD, et al. Tc-99m carbonyl DTPA-Rituximab:Preparation and preliminary bioevaluation[J]. Appl Radiat Isot, 2014, 86(86):52-56. DOI:10.1016/j.apradiso.2013.12.036.

[9]

李艳, 李囡, 翟士桢, 等.特异性前哨淋巴结显像剂⁹⁹Tc^m-rituximab药盒的制备及生物评价[J].同位素, 2011, 24(z1):85-89.
Li Y, Li N, Zhai SZ, et al. Preparation and evaluation of a freeze-dried kit of ⁹⁹Tc^m-rituximab for sentinel lymph node imaging[J]. Isotopes, 2011, 24(z1):85-89.

[10]

Li N, Wang XE, Lin BH, et al. Clinical evaluation of Tc-99m-Rituximab for sentinel lymph node mapping in breast cancer patients[J]. J Nucl Med, 2016, 57(8):1214-1220. DOI:10.2967/jnumed.115.160572.

[11]

丛斌斌, 孙晓, 宋现让, 等.新型前哨淋巴结示踪剂的制备及动物实验研究[J].中国癌症杂志, 2016, 26(3):245-250.DOI.10.3969/j.issn.1007-3969.2016.03.007.
Cong BB, Sun X, Song XR, et al. The preparation and experimental study of a new sentinel lymph node tracer[J]. Chin Oncol, 2016, 26(3):245-250.

[12]

Cong BB, Sun X, Song XR, et al. Preparation study of indocyanine green-rituximab:A new receptor-targeted tracer for sentinel lymph node in breast cancer[J]. Oncotarget, 2016, 7(30):47526-47535. DOI:10.18632/oncotarget.10204.

[13]

田崇麟, 孙晓, 刘雁冰, 等.乳腺癌前哨淋巴结活检术新型示踪剂的动物模型研究[J].中国癌症杂志, 2016, 26(7):569-573. DOI:10.19401/j.cnki.1007-3639.2016.07.002.
Tian CL, Sun X, Liu YB, et al. The study of a novel tracer for breast cancer sentinel lymph node biopsy in an animal model[J]. Chin Oncol, 2016, 26(7):569-573. doi: 10.19401/j.cnki.1007-3639.2016.07.002

[14]

Cope FO, Abbruzzese B, Sanders J, et al. The inextricable axis of targeted diagnostic imaging and therapy:An immunological natural history approach[J]. Nucl Med Biol, 2016, 43(3):215-225. DOI:10.1016/j.nucmedbio.2015.11.007.

[15]

Vera DR, Wallace AM, Hoh CK, et al. A synthetic macromolecule for sentinel node detection:^99mTc-DTPA-mannosyl-dextran[J]. J Nucl Med, 2001, 42(6):951-959.

[16]

Hoh CK, Wallace AM, Vera DR. Preclinical studies of[(99m)Tc]DTPA-mannosyl-dextran[J].Nucl Med Biol, 2003, 30(5):457-464. DOI:10.1016/S0969-8051(03)00028-3.

[17]

杨春慧, 李洪玉, 梁积新, 等. ⁹⁹Tc^m标记右旋糖苷衍生物的制备及其生物分布[J].同位素, 2012, 25(3):149-154.
Yang CH, Li HY, Liang JX, et al. Preparation and biodistribution study of ⁹⁹Tc^m labelled dextran conjugates[J]. Isotopes, 2012, 25(3):149-154.

[18]

李洪玉, 梁积新, 杨春慧, 等. ⁹⁹Tc^m标记右旋糖苷衍生物DCM-1的淋巴结摄取和显像[J].同位素, 2013, 26(1):16-22.DOI. 10.7538/tws.2013.26.01.0016. doi: 10.7538/tws.2013.26.01.0016
Li HY, Liang JX, Yang CH, et al. Lymph nodes distribution and imaging study of ⁹⁹Tc^m labeled dextran conjugate DCM-1[J]. Isotopes, 2013, 26(1):16-22. doi: 10.7538/tws.2013.26.01.0016

[19]

Wallace AM, Hoh CK, Ellner SJ, et al. Lymphoseek:a molecular imaging agent for melanoma sentinel lymph node mapping[J]. Ann Surg Oncol, 2007, 14(2):913-921. DOI:10.1245/s10434-006-9099-4.

[20]

Baker JL, Pu MY, Tokin CA, et al. Comparison of[(99m)Tc]tilmanocept and filtered[(99m)Tc]Sulfur colloid for identification of SLNs in breast cancer patients[J]. Ann Surg Oncol, 2015, 22(1):40-45. DOI:10.1245/s10434-014-3892-2.

[21]

Leong SP, Kim J, Ross M, et al. A phase 2 study of (99m)Tc-Tilmanocept in the detection of sentinel lymph nodes in melanoma and breast cancer[J].Ann Surg Oncol, 2011, 18(4):961-969. DOI:10.1245/s10434-010-1524-z.

[22]

Wallace AM, Han LK, Povoski SP, et al. Comparative evaluation of[^99mTc]tilmanocept for sentinel lymph node mapping in breast cancer patients:results of two phase 3 trials[J]. Ann Surg Oncol, 2013, 20(8):2590-2599. DOI:10.1245/s10434-013-2887-8.

[23]

Sondak VK, King DW, Zager JS, et al. Combined analysis of phase Ⅲ trials evaluating[Tc-99m]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically Node-Negative cutaneous melanoma[J]. Ann Surg Oncol, 2013, 20(2):680-688. DOI:10.1245/s10434-012-2612-z.

[24]

Tokin CA, Cope FO, Metz WL, et al. The efficacy of Tilmanocept in sentinel lymph mode mapping and identification in breast cancer patients:a comparative review and meta-nalysis of the 99mTc-labeled nanocolloid human serum albumin standard of care[J]. Clin Exp Metastasis, 2012, 29(7):681-686. DOI:10.1007/s10585-012-9497-x.

[25]

Ting R, Aguilera TA, Crisp JL, et al. Fast F-18 labeling of a Near-Infrared fluorophore enables positron emission tomography and optical imaging of sentinel lymph nodes[J]. Bioconjug Chem, 2010, 21(10):1811-1819. DOI:10.1021/bc1001328.

[26]

Emerson DK, Limmer KK, Hall DJ, et al. A receptor-targeted fluorescent radiopharmaceutical for multireporter sentinel lymph node imaging[J].Radiology, 2012, 265(1):186-193. DOI:10.1148/radiol.12120638.

[27]

Liss MA, Farshchi-Heydari S, Qin ZA, et al. Preclinical evaluation of Robotic-Assisted sentinel lymph node fluorescence imaging[J]. J Nucl Med, 2014, 55(9):1552-1556. DOI:10.2967/jnumed.114. 140871.

[28]

Qin ZT, Hoh CK, Hall DJ, et al. A tri-modal molecular imaging agent for sentinel lymph node mapping[J]. Nucl Med Biol, 2015, 42(12):917-922. DOI:10.1016/j.nucmedbio.2015.07.011.

[29]

Liss MA, Stroup SP, Qin ZT, et al. Robotic-assisted fluorescence sentinel lymph node mapping using multimodal image guidance in an animal model[J]. Urology, 2014, 84(4):9-14. DOI:10.1016/j.urology.2014.06.021.